AS Ametov, A Barinov, PJ Dyck, R Hermann, N … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS— Metabolically stable diabetic patients with symptomatic
(stage 2) diabetic sensorimotor polyneuropathy (DSPN) were randomized to a parallel,
double-blind study of ALA (600 mg) (n = 60) or placebo (n = 60) infused daily ... Cited by 173 - Related articles - BL Direct - All 7 versions
D Ziegler, H Nowak, P Kempler, P Vargha, PA Low - Diabetic Medicine, 2004 - ecopharm.bg Page 1. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic
acid: A meta-analysis D. Ziegler1, H. Nowak2, and PA Low3 1German Diabetes Research
Institute at the Heinrich Heine University, Düsseldorf, Germany ... Cited by 179 - Related articles - View as HTML - BL Direct - All 10 versions
- ►diabetesjournals.org [PDF] D Ziegler, M Hanefeld, KJ Ruhnau, H Hasche, M … - Diabetes Care, 1999 - Am Diabetes Assoc CONCLUSIONS — These findings indi- cate that a 3-week intravenous treatment with -lipoic
acid, followed by a 6-month oral tre a t- ment, had no effect on neuropathic symptoms distinguishable
from placebo to a clinically meaningful degree, possibly due to incre asing inte rcenter ... Cited by 193 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org D Ziegler, A Ametov, A Barinov, PJ Dyck, I Gurieva, … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this multicenter, randomized, double-blind,
placebo-controlled trial, 181 diabetic patients in Russia and Israel received once-daily oral doses
of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200), and 1,800 mg (ALA1800) of ... Cited by 99 - Related articles - BL Direct - All 6 versions
KCJ Yuen, NR Baker, G Rayman - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The study was of double-blind, randomized,
placebo-controlled, and two-period cross-over design. After a 2-week run-in period, 22 diabetic
patients (13 men, 20 with type 2 diabetes, age [mean ± SE] 63.7 ± 1.8 years, duration of ... Cited by 64 - Related articles - BL Direct - All 6 versions
D Ziegler, M Hanefeld, KJ Ruhnau, HP Mei\ ner, M … - Diabetologia, 1995 - Springer Summary Anti-oxidant treatment has been shown to prevent nerve dysfunction in experimental
diabetes mellitus, thus providing a rationale of potential thera- peutic value for diabetic
patients. The effects of the anti-oxidant a-lipoic acid (thioctic acid) were stud- ied in a ... Cited by 268 - Related articles - BL Direct - All 4 versions
D Ziegler, H Schatz, F Conrad, FA Gries, H Ulrich, G … - Diabetes Care, 1997 - Am Diabetes Assoc OBJECTIVE: To evaluate the efficacy and safety of oral treatment with the antioxidant alpha-lipoic
acid (ALA) in NIDDM patients with cardiac autonomic neuropathy (CAN), assessed by heart rate
variability (HRV). RESEARCH DESIGN AND METHODS: In a randomized, double-blind ... Cited by 108 - Related articles - All 7 versions
- ►diabetesjournals.org [PDF] MJ Stevens, I Obrosova, X Cao, C Van Huysen, DA … - Diabetes, 2000 - Am Diabetes Assoc Experimental diabetic peripheral neuropathy (DPN) is marked by impaired nerve conduction
velocity (NCV), reduced nerve blood flow (NBF), and a variety of meta- bolic abnormalities in
peripheral nerve that have been variously ascribed to hyperglycemia, abnormal fatty acid ... Cited by 154 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org LJ Coppey, JS Gellett, EP Davidson, JA Dunlap, DD … - Diabetes, 2001 - Am Diabetes Assoc We have shown that diabetes-induced reduction in endoneurial blood flow (EBF) and impaired
endothelium-dependent vascular relaxation precede slowing of motor nerve conduction velocity
(MNCV) and decreased sciatic nerve Na + /K + ATPase activity. Furthermore, vascular ... Cited by 131 - Related articles - BL Direct - All 6 versions
